EUROPEAN SOCIETY OF THORACIC SURGEONS COLLABORATES WITH ASTRAZENECA
20 July 2021
(Last updated: 20 Jul 2021 08:30)
The European Society of Thoracic Surgeons (ESTS) is proud to announce an exciting new collaboration with AstraZeneca that will support initiatives aimed at optimizing and harmonizing the use of surgery and systemic therapies in the treatment of early-stage lung cancer to improve the outcomes of surgical patients.
The new collaboration with AstraZeneca will greatly support and enhance the activities and scope of ESTS. This important collaboration will broaden the possibilities for ESTS to embark in important areas of thoracic oncology and will involve all members, contributing to expand their knowledge for the betterment of our specialty and our surgical patients.
Additionally, by supporting fellowships, this partnership will greatly enhance the career development opportunities of ESTS members who will be able to acquire novel research techniques or enable an early career thoracic surgeon to implement new surgical skills and expand thoracic surgeons knowledge in systemic therapies for lung cancer patients in early stages.
With the support of AstraZeneca, ESTS will facilitate to educate ESTS members about current and future systemic treatments in resectable NSCLC and their impact on staging and surgery. This will improve the knowledge of participants with up-to-date, evidence-based data on indications of neoadjuvant and adjuvant therapies.
AstraZeneca has committed nearly 700.000 EURO in sponsorship for support of these projects, which will ultimately improve the care of thoracic surgical patients.
AstraZeneca is a leader in the evolving management of early-stage lung cancer, with the goal of helping to improve the quality of life and life expectancy of people with lung cancer. This is in full synergy with the ESTS mission aimed at improving patient care through education and training.
ESTS is the largest global organisation focusing purely on General Thoracic Surgery with over 1600 members from all over the world. The international representation is reflected by a large attendance at the annual meetings from all continents. ESTS has developed from a Club of thoracic surgeons in the mid-seventies to the foundation of a Society in 1993 which has since grown in strength and success over the years.
ESTS is delighted that the collaboration with AstraZeneca will benefit the whole thoracic oncology community and lung cancer patients by educating the next generation of thoracic surgeons and supporting ESTS in developing important future trials in total alignment with the respective missions of the two organisations.
Isabelle Opitz Alessandro Brunelli
Treasurer and President Elect President ESTS
Hasan Batirel Nuria Novoa
Secretary General Director of Education
20 July 2021
View other News Articles